Teknova Reports Second Quarter 2022 Financial Results

Rhea-AI Summary

Alpha Teknova reported a total revenue of $11.7 million for Q2 2022, representing a 41% year-over-year increase. The company maintains a cash position of $64.7 million to support ongoing growth investments and has adjusted its 2022 revenue outlook to $38-42 million. Although they experienced healthy demand, Teknova acknowledges potential revenue slowdown in H2 2022 due to biopharma customers deferring purchases. Gross profit reached $5.2 million, with a 44.9% gross margin, despite increased operating expenses of $11.9 million and a net loss of $6.2 million.

Positive

• Total revenue up 41% year-over-year to $11.7 million.
• Cash position of $64.7 million supports growth.
• 2022 revenue outlook adjusted to $38-42 million, indicating continued growth.

Negative

• Net loss of $6.2 million for Q2 2022, worsened from loss of $2.3 million in Q2 2021.
• Operating expenses increased to $11.9 million, up from $5.9 million in Q2 2021.
• Higher labor and overhead costs leading to gross margin decline.

Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year
Cash position of $64.7 million supports ongoing investment in growth strategy
Company updates 2022 revenue outlook to $38-42 million

HOLLISTER, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2022.

“We were pleased with our second quarter revenue growth and the excellent progress on the build-out of our new manufacturing facility,” said Stephen Gunstream, President and CEO of Teknova. “While we continue to see healthy demand across our broader customer base, we now expect lower than anticipated revenue in the second half of 2022, we believe in large part due to certain of our early-stage biopharma customers deferring large purchases. We nonetheless remain confident in our fundamental growth opportunity and our position in the market.”

Corporate and Financial Updates

• Achieved record quarterly total revenue of $11.7 million, up 41%, compared to $8.3 million in the second quarter 2021
• Remained on track with capacity expansion of existing facilities and the construction of a new, state-of-the-art manufacturing facility
• Reported cash position of $64.7 million, supporting ongoing investment in future growth

Revenue for the Second Quarter and Year-to-Date 2022

(Dollars in Thousands)		For the Three Months Ended June 30,						For the Six Months Ended June 30,
Unaudited			2022			2021			2022			2021
Lab Essentials		$	8,393		$	6,456		$	15,368		$	13,246
Clinical Solutions			2,943			1,593			6,755			2,664
Sample Transport			—			37			6			961
Other			354			227			708			520
Total Revenue		$	11,690		$	8,313		$	22,837		$	17,391

Second Quarter 2022 Financial Results

Total revenue for the second quarter 2022 was $11.7 million, up 41%, compared to $8.3 million in the second quarter 2021.

Gross profit for the second quarter 2022 was $5.2 million, compared to $3.4 million in the second quarter 2021. Gross margin for the second quarter 2022 was 44.9% of revenue. This compares to gross margin of 40.3% in the second quarter 2021, and gross margin of 48.7% in the second quarter 2021 on an adjusted basis, which excludes the impact of a $0.7 million charge from an inventory reserve related to excess Sample Transport inventory. The lower gross margin for the second quarter 2022 compared to the adjusted gross margin in the prior year reflects higher labor and overhead costs.

Operating expenses for the second quarter 2022 were $11.9 million, compared to $5.9 million in the second quarter 2021. The increase was primarily related to additional headcount, marketing costs, and stock-based compensation expenses.

Net loss for the second quarter 2022 was $6.2 million, or negative $0.22 per diluted share, compared to net loss of $2.3 million, or negative $0.52 per diluted share, for the second quarter 2021.

Cash used in operating activities for the second quarter 2022 was $5.8 million, compared to cash used in operating activities of $3.6 million for the second quarter 2021.

Adjusted EBITDA for the second quarter 2022 was negative $4.9 million, compared to negative $1.5 million for the second quarter 2021. Free Cash Flow was negative $16.8 million for the second quarter 2022, compared to negative $8.2 million for the second quarter 2021.

2022 Revenue Outlook

Teknova now anticipates total revenue of $38 million to $42 million for the fiscal year ending December 31, 2022, which assumes approximately 13% growth at the mid-point of guidance, excluding Sample Transport revenue. Total revenue growth is expected to be driven by an approximately 10% increase in Lab Essentials and at least a 45% increase in Clinical Solutions. The Company does not anticipate any material revenue from Sample Transport in 2022.

Conference Call and Webcast

Teknova will host a webcast and conference call on Wednesday, August 10, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/s88ivr8z. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BI212f2574e2aa4cf68a5e40a4de877e89. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova

Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.

Non-GAAP Financial Measures

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of our business and the effectiveness of our business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.

Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, benefit from income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that we do not consider representative of our ongoing operating performance.

Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.

Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in our industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in our operating results because they exclude items that are not indicative of our core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to our anticipated total revenue, our expectation that recent customer engagement dynamics will be transitory, and growth in Lab Essentials and growth in Clinical Solutions for 2022, and statements about our prospects and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, demand for our products (including the delay or pausing of customer orders); our assessment of fundamental indicators of future demand across our target customer base; our ability to expand our production capacity and commercial and R&D capabilities; our cash flows and revenue growth rate; our supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic, including the impact of the pandemic on our supply chain; reliance on a limited number of customers for a high percentage of our revenue; potential acquisitions and integration of other companies and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
			2022				2021				2022				2021
Revenue		$	11,690			$	8,313			$	22,837			$	17,391
Cost of sales			6,443				4,959				12,241				9,012
Gross profit			5,247				3,354				10,596				8,379
Operating expenses:
Research and development			1,929				851				3,942				1,548
Sales and marketing			2,598				904				4,195				1,609
General and administrative			7,059				3,838				14,354				8,002
Amortization of intangible assets			287				287				574				574
Total operating expenses			11,873				5,880				23,065				11,733
Loss from operations			(6,626	)			(2,526	)			(12,469	)			(3,354	)
Other income (expenses), net
Interest income (expense), net			28				(304	)			15				(296	)
Other expense, net			—				(3	)			—				(2	)
Total other income (expenses), net			28				(307	)			15				(298	)
Loss before income taxes			(6,598	)			(2,833	)			(12,454	)			(3,652	)
Benefit from income taxes			(395	)			(583	)			(754	)			(747	)
Net loss		$	(6,203	)		$	(2,250	)		$	(11,700	)		$	(2,905	)
Net loss per share—basic and diluted		$	(0.22	)		$	(0.52	)		$	(0.42	)		$	(0.73	)
Weighted average shares used in computing net loss per share—basic and diluted			28,057,801				4,328,222				28,044,460				3,965,741

ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited)
(In thousands)

	As of June 30,				As of December 31,
		2022				2021
ASSETS
Current assets:
Cash and cash equivalents	$	64,734			$	87,518
Accounts receivable, net		5,810				4,666
Inventories, net		7,909				5,394
Income taxes receivable		117				1,188
Prepaid expenses and other current assets		1,701				2,438
Total current assets		80,271				101,204
Property, plant and equipment, net		47,258				29,810
Operating right-of-use lease assets		19,154				—
Goodwill		16,613				16,613
Intangible assets, net		18,130				18,704
Other non-current assets		769				180
Total assets	$	182,195			$	166,511
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,421			$	2,248
Accrued liabilities		8,250				5,495
Current portion of operating lease liabilities		2,194				—
Total current liabilities		11,865				7,743
Deferred tax liabilities		2,402				3,153
Other accrued liabilities		233				273
Long-term debt, net		16,818				11,870
Deferred rent		—				269
Long-term operating lease liabilities		17,410				—
Total liabilities		48,728				23,308
Stockholders’ equity:
Preferred stock		—				—
Common stock		—				—
Additional paid-in capital		152,705				150,741
Accumulated deficit		(19,238	)			(7,538	)
Total stockholders’ equity		133,467				143,203
Total liabilities and stockholders’ equity	$	182,195			$	166,511

ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
			2022				2021				2022				2021
Operating activities:
Net loss		$	(6,203	)		$	(2,250	)		$	(11,700	)		$	(2,905	)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense			25				319				32				231
Inventory reserve			(4	)			701				(8	)			699
Depreciation and amortization			792				700				1,543				1,352
Stock-based compensation			934				302				1,721				485
Deferred taxes			(391	)			(583	)			(751	)			(747	)
Amortization of debt financing costs			53				46				99				46
Non-cash lease expense			75				49				181				49
Other			—				4				—				(6	)
Changes in operating assets and liabilities:
Accounts receivable			143				(66	)			(1,176	)			334
Inventories			(1,479	)			(702	)			(2,507	)			(997	)
Income taxes receivable			1,071				(44	)			1,071				(221	)
Prepaid expenses and other current assets			190				70				737				418
Accounts payable			(515	)			(1,316	)			(278	)			(33	)
Accrued liabilities			(136	)			(642	)			626				205
Other			(393	)			(139	)			(629	)			(60	)
Cash used in operating activities			(5,838	)			(3,551	)			(11,039	)			(1,150	)
Investing activities:
Purchase of property, plant and equipment			(10,920	)			(4,674	)			(16,837	)			(8,558	)
Proceeds from loan to related party			—				—				—				529
Proceeds on sales of short-term marketable securities			—				—				—				1,132
Proceeds from maturities of short-term marketable securities			—				—				—				695
Cash used in investing activities			(10,920	)			(4,674	)			(16,837	)			(6,202	)
Financing activities:
Proceeds from long-term debt			5,135				—				5,135				11,889
Payment of debt issuance costs			(151	)			—				(151	)			(153	)
Payment of exit fee costs			(135	)			—				(135	)			—
Payment of costs related to initial public offering			—				(891	)			—				(2,349	)
Proceeds from initial public offering, net of underwriters’ commissions and discounts			—				102,672				—				102,672
Proceeds from exercise of stock options			44				—				99				—
Proceeds from issuance of common stock under employee stock purchase plan			144				—				144				—
Cash provided by financing activities			5,037				101,781				5,092				112,059
Change in cash and cash equivalents			(11,721	)			93,556				(22,784	)			104,707
Cash and cash equivalents at beginning of period			76,455				14,466				87,518				3,315
Cash and cash equivalents at end of period		$	64,734			$	108,022			$	64,734			$	108,022

ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(Unaudited)
(In thousands)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
			2022				2021				2022				2021
Net loss – as reported		$	(6,203	)		$	(2,250	)		$	(11,700	)		$	(2,905	)
Add back:
Interest income (expense), net			28				(304	)			15				(296	)
Benefit from income taxes			(395	)			(583	)			(754	)			(747	)
Depreciation expense			505				413				969				778
Amortization of intangible assets			287				287				574				574
EBITDA		$	(5,834	)		$	(1,829	)		$	(10,926	)		$	(2,004	)
Other and one-time expenses:
Stock-based compensation expense			934				302				1,721				485
Adjusted EBITDA		$	(4,900	)		$	(1,527	)		$	(9,205	)		$	(1,519	)
		For the Three Months Ended June 30,								For the Six Months Ended June 30,
			2022				2021				2022				2021
Cash used in operating activities		$	(5,838	)		$	(3,551	)		$	(11,039	)		$	(1,150	)
Purchase of property, plant and equipment			(10,920	)			(4,674	)			(16,837	)			(8,558	)
Free Cash Flow		$	(16,758	)		$	(8,225	)		$	(27,876	)		$	(9,708	)

FAQ

What were Alpha Teknova's total revenues for Q2 2022?

Alpha Teknova reported total revenues of $11.7 million for Q2 2022.

What is the outlook for Teknova's revenue in 2022?

Teknova expects total revenue for 2022 to be in the range of $38-42 million.

How much cash does Teknova have available for investment?

Teknova has a cash position of $64.7 million to support its growth strategy.

What was Teknova's net loss for Q2 2022?

Teknova reported a net loss of $6.2 million for the second quarter of 2022.

What were the operating expenses for Teknova in Q2 2022?

Operating expenses for Q2 2022 were $11.9 million, significantly higher than the previous year.